Neoplasms

3,876 trials 1,551 recruiting

Filter these 3,876 trials by phase, country and sponsor.

Open in Search →

Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending

2024-517133-40-00 newly diagnosed, non-metastatic, SHH-activated, TP53-wt 5
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending

2025-522019-40-00 relapsed or refractory BCR::ABL1-positive (Philadelphia 9
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending

2025-523285-25-00 Relapsed or Refractory Multiple Myeloma 5
Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma… Pending

2025-524031-39-00 Medulloblastoma (recurrent or progressive) 3
A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix … Pending

2023-509255-14-01 Advanced prostate cancer 4
A trial to learn how safe AZD9793 is, how it moves throughout the body over time, how it affects the body, and how well it works in adults w… Pending

2024-516698-56-00 Hepatocellular Carcinoma 7
A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. Pending

2025-522595-87-00 Hematological Malignancies 7
A Phase 2 Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects w… Pending

2024-518627-29-00 locally advanced pancreatic cancer 4
Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation Pending

2025-522027-95-00 oral squamous cell carcinoma 5
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatini… Pending

2025-524935-38-00 Acute Lymphoblastic Leukemia (Ph+ ALL) 2
Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastase… Pending

2024-517149-15-00 Rectal cancer 6
CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRI… Pending

2024-517639-35-00 Non-Hodgkin lymphomas (NHL) 9
Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroen… Pending

2025-524942-87-00 Gastroenteropancreatic neuroendocrine tumors 6
A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123… Pending

2024-520258-39-00 Solid Tumors 3
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv… Pending

2025-524048-36-00 Advanced HER2-negative and PD-L1 positive gastroesophag 5
64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer Pending

2025-520861-29-00 Prostate cancer at risk of developing metastatic lesion 5
Use of the diagnostic PET with 64CuCl2 in order to select patients, in which a disease relapse is shown after prostate surgical removal, to … Pending

2025-520868-17-00 Cancer on the prostatic bed 5
uPAR PET/MRI in glioma Pending

2024-519723-20-01 Glioma 9
A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps Pending

2025-522045-21-00 Solid tumours 1
Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial Pending

2023-507214-28-00 Advanced thyroid cancer 3
Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial) Pending

2024-516718-39-00 Melanoma 6
A study to investigate WEF-001 in patients with Advanced KRAS-Mutant Solid Tumours. Pending

2024-518644-21-01 Advanced KRAS- Mutant Solid Tumours 9
Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib Pending

2025-523340-12-00 Glioma 3
Study on the feasibility of fluorescence bronchoscopy with bevacizumab-800CW - DEFLECT I Pending

2024-510793-24-00 suspected malignant pulmonary disease (lung lesions and 4